BioCryst has agreed to sell its European business based on hereditary angioedema (HAE) therapy Orladeyo to Italy's Neopharmed ...

GRIN-related neurodevelopmental disorder (GRIN-NDD) is a family of rare, genetically defined neurodevelopmental disorders ...

It's a shot in the arm for Cambridge, Massachusetts-based Moderna as it faces an evolving regulatory environment for vaccines ...

Since the first-generation CAR-Ts reached the market several years ago, clinicians have become more adept at handling ...

ASCO 2025 spotlighted new data across haematologic cancers this year. To discuss announcements in liquid cancers further, as opposed to solid tumours, pharmaphorum spoke with Dr Lore Gruenbaum, chief ...

Faced with the prospect of tariffs on imported medicines threatened by the Trump administration, Indian drugmaker Hikma has said it will spend $1 billion to expand its manufacturing and R&D operations ...

At Axtria Ignite 2025 in Princeton, New Jersey, web editor Nicole Raleigh spoke with the company’s co-founder, president, and CEO Jaswinder Chadha. An AI-first data analytics innovator focused on ...

Shares in INmune Bio lost almost two-thirds of their value in premarket trading this morning as it emerged that its drug candidate for Alzheimer's disease flunked a highly anticipated phase 2 trial.

The UK is studying cases of pancreatitis in people taking drugs based on GLP-1 receptor agonists for weight loss or type 2 ...

Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

At BIO 2025, pharmaphorum Editor in Chief spoke with Hanadie Yousef, CEO of Juvena Therapeutics, a biotech focused on ...

The Neuropsychiatric Drug Development Summit returns for its eighth year as the industry’s flagship forum capturing ...